Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma
- 7 August 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (6) , 707-716
Abstract
The therapeutic success of first-line quadruplet (QUAD) induction therapy and autologous stem cell transplantation (ASCT) has reinvigorated an interest in fixed-duration therapy, yet optimal short-term efficacy end point for treatment cessation is unknown. Using data from a phase 2 clinical trial and a prospective institutional database, we tested the predictive performance of 5 short-term efficacy end points among 221 patients who received QUAD + ASCT followed by treatment cessation if minimal residual disease (MRD) by next-generation sequencing negative for 2 consecutive time points. Efficacy end points tested were International Myeloma Working Group–defined stringent complete response, MRD <10–5 (single data point), MRD <10–6, sustained MRD (S-MRD; 2 consecutive assessments at least 1 year apart) <10–5, and S-MRD <10–6. We built 5 parallel Cox regression models for each efficacy end point with progression-free survival (PFS) as the outcome. Best fitting models were determined using the Akaike information criterion (AIC) and Heagerty and Zheng C-index. The best fitting model (AIC, 417.2; C statistic, 0.757) was based on S-MRD <10–5 (hazard ratio, 0.23; 95% confidence interval, 0.11-0.47). Similar results were seen for predicting the risk of progression/MRD resurgence among 121 patients undergoing MRD-guided treatment cessation. S-MRD <10–5 is the best predictor of PFS and yields the best predictive models for the risk of MRD resurgence or progression in the setting of fixed-duration therapy. This trial was registered at www.clinicaltrials.gov as #NCT03224507.Keywords
This publication has 23 references indexed in Scilit:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialThe Lancet Oncology, 2024
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskBlood Cancer Journal, 2024
- Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2023
- Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialThe Lancet Haematology, 2023
- Pitfalls of the concordance index for survival outcomesStatistics in Medicine, 2023
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Autologous Transplantation and Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine, 2014
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- A new measure of prognostic separation in survival dataStatistics in Medicine, 2004
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996